VMD Quote, Financials, Valuation and Earnings

Electromed has a net margin of 4.44% compared to Viemed Healthcare's net margin of 12.06%. Viemed Healthcare's return on equity of 9.69% beat Electromed's return on equity of 16.57%.

Viemed Healthcare has a consensus price target of $11.75, signalling upside risk potential of 69.8%. On the other hand Electromed has an analysts' consensus of $38.00 which suggests that it could grow by 72.81%. Given that Electromed has higher upside potential than Viemed Healthcare, analysts believe Electromed is more attractive than Viemed Healthcare.

Viemed Healthcare has a beta of 1.378, which suggesting that the stock is 37.796% more volatile than S&P 500. In comparison Electromed has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.159%.

Viemed Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viemed Healthcare pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Viemed Healthcare quarterly revenues are $59.1M, which are larger than Electromed quarterly revenues of $15.7M. Viemed Healthcare's net income of $2.6M is higher than Electromed's net income of $1.9M. Notably, Viemed Healthcare's price-to-earnings ratio is 23.07x while Electromed's PE ratio is 27.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viemed Healthcare is 1.22x versus 3.21x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX has a net margin of 4.44% compared to Viemed Healthcare's net margin of -14.17%. Viemed Healthcare's return on equity of 9.69% beat IRIDEX's return on equity of -218.69%.

Viemed Healthcare has a consensus price target of $11.75, signalling upside risk potential of 69.8%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 127.27%. Given that IRIDEX has higher upside potential than Viemed Healthcare, analysts believe IRIDEX is more attractive than Viemed Healthcare.

Viemed Healthcare has a beta of 1.378, which suggesting that the stock is 37.796% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.615, suggesting its less volatile than the S&P 500 by 38.546%.

Viemed Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viemed Healthcare pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

Viemed Healthcare quarterly revenues are $59.1M, which are larger than IRIDEX quarterly revenues of $11.9M. Viemed Healthcare's net income of $2.6M is higher than IRIDEX's net income of -$1.7M. Notably, Viemed Healthcare's price-to-earnings ratio is 23.07x while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viemed Healthcare is 1.22x versus 0.30x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of 4.44% compared to Viemed Healthcare's net margin of -35.24%. Viemed Healthcare's return on equity of 9.69% beat Myomo's return on equity of -38.11%.

Viemed Healthcare has a consensus price target of $11.75, signalling upside risk potential of 69.8%. On the other hand Myomo has an analysts' consensus of $8.70 which suggests that it could grow by 284.96%. Given that Myomo has higher upside potential than Viemed Healthcare, analysts believe Myomo is more attractive than Viemed Healthcare.

Viemed Healthcare has a beta of 1.378, which suggesting that the stock is 37.796% more volatile than S&P 500. In comparison Myomo has a beta of 1.489, suggesting its more volatile than the S&P 500 by 48.933%.

Viemed Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viemed Healthcare pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Viemed Healthcare quarterly revenues are $59.1M, which are larger than Myomo quarterly revenues of $9.8M. Viemed Healthcare's net income of $2.6M is higher than Myomo's net income of -$3.5M. Notably, Viemed Healthcare's price-to-earnings ratio is 23.07x while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viemed Healthcare is 1.22x versus 2.28x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of 4.44% compared to Viemed Healthcare's net margin of -77.93%. Viemed Healthcare's return on equity of 9.69% beat Stereotaxis's return on equity of -174.6%.

Viemed Healthcare has a consensus price target of $11.75, signalling upside risk potential of 69.8%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 96.51%. Given that Stereotaxis has higher upside potential than Viemed Healthcare, analysts believe Stereotaxis is more attractive than Viemed Healthcare.

Viemed Healthcare has a beta of 1.378, which suggesting that the stock is 37.796% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.460, suggesting its more volatile than the S&P 500 by 46.028%.

Viemed Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viemed Healthcare pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Viemed Healthcare quarterly revenues are $59.1M, which are larger than Stereotaxis quarterly revenues of $7.5M. Viemed Healthcare's net income of $2.6M is higher than Stereotaxis's net income of -$5.8M. Notably, Viemed Healthcare's price-to-earnings ratio is 23.07x while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viemed Healthcare is 1.22x versus 7.18x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.